24/7 Market News Snapshot 29 August, 2025 – NeoGenomics, Inc. (NASDAQ:NEO)

August 29, 2025

DENVER, Colo., 29 August, 2025 (www.247marketnews.com) – (NASDAQ:NEO) are discussed in this article.
NeoGenomics, Inc. has achieved significant advancements in both its stock performance and legal standing. The company’s shares opened at $7.335 and have surged to $8.908, marking a hefty increase of 23.55%. This uptrend represents a robust investor interest compared to the previous day’s closing at $7.210, supported by a trading volume of 1.65 million shares. Technical analysis indicates a strong bullish sentiment, prompting speculation about further gains in the future. Investors are advised to monitor developments closely, especially as the biotech sector continues to evolve rapidly.

Concurrently, NeoGenomics has secured a major legal victory with the District Court for the Middle District of North Carolina ruling in favor of the company by granting its motion for summary judgment. This ruling invalidates all patent claims brought forth by Natera, affirming that these claims pertain to ineligible subject matter. The court’s decision will lead to the dismissal of Natera’s claims against NeoGenomics with prejudice, allowing the company to operate unencumbered by this legal challenge.

This ruling significantly strengthens NeoGenomics’ market position and supports the commercialization of its RaDaR® ST assay, an enhanced version of its innovative liquid biopsy test. The RaDaR ST assay is now accessible to biopharma clients and has been submitted for reimbursement coverage under the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program, reflecting NeoGenomics’ commitment to improving diagnostic options in oncology.

Tony Zook, CEO of NeoGenomics, expressed optimism regarding the court’s decision, reaffirming the company’s dedication to advancing personalized cancer care through comprehensive diagnostic testing solutions. This victory not only bolsters NeoGenomics’ intellectual property stance but also exemplifies its ongoing commitment to innovation and excellence in the oncology diagnostics arena.

Related news for (NEO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.